000265958 001__ 265958
000265958 005__ 20240403103732.0
000265958 0247_ $$2pmc$$apmc:PMC10647047
000265958 0247_ $$2doi$$a10.1186/s12888-023-05346-y
000265958 0247_ $$2pmid$$apmid:37964300
000265958 0247_ $$2altmetric$$aaltmetric:156452845
000265958 037__ $$aDZNE-2023-01081
000265958 041__ $$aEnglish
000265958 082__ $$a610
000265958 1001_ $$aLütt, A.$$b0
000265958 245__ $$aAn explorative single-arm clinical study to assess craving in patients with alcohol use disorder using Virtual Reality exposure (CRAVE)-study protocol.
000265958 260__ $$aHeidelberg$$bSpringer$$c2023
000265958 3367_ $$2DRIVER$$aarticle
000265958 3367_ $$2DataCite$$aOutput Types/Journal article
000265958 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1700491428_2200
000265958 3367_ $$2BibTeX$$aARTICLE
000265958 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000265958 3367_ $$00$$2EndNote$$aJournal Article
000265958 520__ $$aAlcohol use disorder (AUD) belongs to the most burdensome clinical disorders worldwide. Current treatment approaches yield unsatisfactory long-term effects with relapse rates up to 85%. Craving for alcohol is a major predictor for relapse and can be intentionally induced via cue exposure in real life as well as in Virtual Reality (VR). The induction and habituation of craving via conditioned cues as well as extinction learning is used in Cue Exposure Therapy (CET), a long-known but rarely used strategy in Cognitive Behavioral Therapy (CBT) of AUD. VR scenarios with alcohol related cues offer several advantages over real life scenarios and are within the focus of current efforts to develop new treatment options. As a first step, we aim to analyze if the VR scenarios elicit a transient change in craving levels and if this is measurable via subjective and psychophysiological parameters.A single-arm clinical study will be conducted including n = 60 patients with AUD. Data on severity of AUD and craving, comorbidities, demographics, side effects and the feeling of presence in VR will be assessed. Patients will use a head-mounted display (HMD) to immerse themselves into three different scenarios (neutral vs. two target situations: a living room and a bar) while heart rate, heart rate variability, pupillometry and electrodermal activity will be measured continuously. Subjective craving levels will be assessed before, during and after the VR session.Results of this study will yield insight into the induction of alcohol craving in VR cue exposure paradigms and its measurement via subjective and psychophysiological parameters. This might be an important step in the development of innovative therapeutic approaches in the treatment of patients with AUD.This study was approved by the Charité-Universitätsmedizin Berlin Institutional Review Board (EA1/190/22, 23.05.2023). It was registered on ClinicalTrials.gov (NCT05861843).
000265958 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000265958 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000265958 650_7 $$2Other$$aAlcohol Use Disorder
000265958 650_7 $$2Other$$aCraving
000265958 650_7 $$2Other$$aCue Exposure Therapy
000265958 650_7 $$2Other$$aElectrodermal activity
000265958 650_7 $$2Other$$aHeart rate variability
000265958 650_7 $$2Other$$aPsychophysiological parameters
000265958 650_7 $$2Other$$aPupillometry
000265958 650_7 $$2Other$$aVirtual Reality
000265958 650_2 $$2MeSH$$aHumans
000265958 650_2 $$2MeSH$$aAlcohol Drinking
000265958 650_2 $$2MeSH$$aAlcoholism: therapy
000265958 650_2 $$2MeSH$$aAlcoholism: psychology
000265958 650_2 $$2MeSH$$aCraving
000265958 650_2 $$2MeSH$$aCues
000265958 650_2 $$2MeSH$$aRecurrence
000265958 650_2 $$2MeSH$$aVirtual Reality
000265958 7001_ $$aTsamitros, N.$$b1
000265958 7001_ $$0P:(DE-2719)2810583$$aWolbers, T.$$b2$$udzne
000265958 7001_ $$aRosenthal, A.$$b3
000265958 7001_ $$aBröcker, A. L.$$b4
000265958 7001_ $$aSchöneck, R.$$b5
000265958 7001_ $$aBermpohl, F.$$b6
000265958 7001_ $$aHeinz, A.$$b7
000265958 7001_ $$aBeck, A.$$b8
000265958 7001_ $$aGutwinski, S.$$b9
000265958 773__ $$0PERI:(DE-600)2050438-X$$a10.1186/s12888-023-05346-y$$gVol. 23, no. 1, p. 839$$n1$$p839$$tBMC psychiatry$$v23$$x1471-244X$$y2023
000265958 8564_ $$uhttps://pub.dzne.de/record/265958/files/DZNE-2023-01081.pdf$$yOpenAccess
000265958 8564_ $$uhttps://pub.dzne.de/record/265958/files/DZNE-2023-01081.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000265958 909CO $$ooai:pub.dzne.de:265958$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000265958 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810583$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000265958 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000265958 9141_ $$y2023
000265958 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000265958 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000265958 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBMC PSYCHIATRY : 2022$$d2023-08-28
000265958 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-28
000265958 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-28
000265958 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-28
000265958 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-05-02T09:05:40Z
000265958 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-05-02T09:05:40Z
000265958 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review$$d2023-05-02T09:05:40Z
000265958 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-28
000265958 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-28
000265958 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-28
000265958 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-28
000265958 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-28
000265958 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-28
000265958 9201_ $$0I:(DE-2719)1310002$$kAG Wolbers$$lAging, Cognition and Technology$$x0
000265958 980__ $$ajournal
000265958 980__ $$aVDB
000265958 980__ $$aUNRESTRICTED
000265958 980__ $$aI:(DE-2719)1310002
000265958 9801_ $$aFullTexts